TABLE 2.
Neurologic Complications by Viral Disease
| Neurologic finding | Number of patients | Percent |
|---|---|---|
| H1N1 | ||
| Headache | 541 | 6.73% |
| Seizure | 228 | 2.84% |
| Encephalitis/encephalopathy(often grouped together) | 76 | 0.95% |
| Weakness | 41 | 0.51% |
| Altered level of consciousness | 22 | 0.27% |
| Meningitis | 13 | 0.16% |
| Speech difficulties | 6 | 0.07% |
| Cognitive and memory issues | 5 | 0.06% |
| Cranial nerve or focal deficit | 5 | 0.06% |
| Neurological long-termcomplications, not specified | 5 | 0.06% |
| Stroke | 4 | 0.05% |
| Guillain-Barré syndrome | 3 | 0.04% |
| Hearing impairment andtinnitus | 1 | 0.01% |
| MERS | ||
| Headache | 147 | 13.03% |
| Altered level of consciousness | 136 | 12.06% |
| Cognitive or memory issues | 18 | 1.60% |
| Cranial nerve or focal deficit | 10 | 0.89% |
| Seizure | 6 | 0.53% |
| SARS | ||
| Headache | 109 | 8.71% |
| Dizziness | 60 | 4.80% |
| Stroke | 10 | 0.80% |
| Altered level of consciousness | 5 | 0.40% |
| Neuropathy | 3 | 0.24% |
| COVID-19 | ||
| Headache | 620 | 11.74% |
| Dizziness | 62 | 1.17% |
| Altered level of consciousness | 62 | 1.17% |
| Diminished taste sensation | 12 | 0.23% |
| Diminished smell | 11 | 0.21% |
| Stroke | 6 | 0.11% |
| Neuralgia | 5 | 0.09% |
| Seizure | 2 | 0.04% |
| Ataxia | 1 | 0.02% |